REALQUALITY RQ-PML-RARa bcr3 One-Step

Description

Kit for detection and quantification of translocation t(15;17)(q22;q21), in variant bcr3, by one-step Real-Time RT-PCR

Product Characteristics

• The device is developed in accordance with the guidelines of Europe Against Cancer and international recommendations
• The assay includes dUTP/UNG system for preventing carry-over contamination and a fluorescence normalizer
• The assay requires only 5 µL of RNA extracted
• If used together with the product REALQUALITY RQ-PML-RARa bcr3 STANDARD, the kit allows the absolute quantification of the number of PML-RARa bcr3 transcripts present in the test sample, normalized to the number of transcripts of the housekeeping ABL gene
• The assay shares the same thermal profile of REALQUALITY RQ-BCR-ABL p210 One-Step, REALQUALITY RQ-BCR-ABL p190 One-Step, REALQUALITY RQ-PML-RARa bcr1 One-Step e REALQUALITY RQ-PML-RARa bcr2 One-Step kits
• Validated on main Real-Time PCR instruments

Kit content

Kit contains:

• Ready-to-use reagents for Real-Time PCR
• Positive control

Further Information

The translocation t(15;17)(q22;q21) is frequently associated (more than 90% of cases) with Acute Promyelocytic Leukemia (APL), a subtype of Acute Myeloid Leukemia (AML) with M3 cytomorphology. APLs account for 10-15% of AML cases. The translocation t(15;17)(q22;q21) derives from the fusion of the PML gene (promyelocytic leukemia gene), located on chromosome 15q22 and the RARa gene (retinoic acid receptor α) located on chromosome 17q21. The break point in the RARa gene is located within a region of 15 Kb of intron 2; the break point in the PML gene, on the other hand, can occur in three possible regions: intron 6 (55% of cases), intron 3 (40% of cases) and exon 6 (5% of cases). At each break point, a particular PML-RARa isoform is associated, called bcr1, bcr3 and bcr2 respectively. The resulting fusion protein is a transcriptional repressor that hinders the differentiation of hematopoietic stem cells, which remain blocked at the promyelocyte stage. Treatment with ATRA (All Trans Retinoic Acid) is very effective in APL therapy by acting as a promoter of the differentiation process.

Ordering Information